Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere® (Docetaxel) Plus Vectibix® (Panitumumab) in Patients With Operable, HR and Her-2 Negative Breast Cancer. TVA Study

NCT00933517 is registered in ClinicalTrials.gov with Centre Jean Perrin as lead sponsor.

NCT NCT00933517
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00933517 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial Assessing Neoadjuvant Therapy With FEC 100 Followed by Taxotere® (Docetaxel) Plus Vectibix® (Panitumumab) in Patients With Operable, HR and Her-2 Negative Breast Cancer. TVA Study
Lead sponsor
Centre Jean Perrin
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2009
Completion date
October 31, 2011
Enrollment
62 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

pathological response rate